Memory T cells originate from adoptively transferred effectors and reconstituting host cells after sequential lymphodepletion and adoptive immunotherapy
- PMID: 15004146
- DOI: 10.4049/jimmunol.172.6.3462
Memory T cells originate from adoptively transferred effectors and reconstituting host cells after sequential lymphodepletion and adoptive immunotherapy
Abstract
Adoptive transfer of tumor-specific effector T cells induces regression of advanced tumors and induces a long term memory response; however, the origin of this response has not been clearly defined. In this study Thy1.2+ mice bearing advanced MCA-205 tumors were treated with sublethal total body irradiation, followed by adoptive transfer of congenic Thy1.1+ T cells that had been sensitized to tumor in vivo and then activated ex vivo with anti-CD3, IL-2, and IL-7. Splenocytes were recovered >140 days after the initial therapy, and the L-selectinlow memory cell subset was separated into host Thy1.2+ and transferred Thy1.1+ cells and restimulated ex vivo. Both adoptively transferred Thy1.1+ cells as well as reconstituted host Thy1.2+ cells could specifically eliminate MCA-205 pulmonary metastases. Interestingly, hosts with partial responses followed by tumor recurrence nevertheless harbored memory cells that could be isolated and numerically amplified ex vivo to regenerate potent effector function. Memory cells were recovered after adoptive transfer into lymphodepleted nontumor-bearing hosts, indicating that they were not dependent on continued Ag exposure. These experiments establish that rapid ex vivo expansion of tumor Ag-primed T cells does not abrogate their capacity to become long-lived memory cells. Moreover, immune-mediated tumor regression coincident with lymphoid reconstitution produces another wave of host memory cells. These data suggest an approach to rescuing antitumor immune function even in hosts with long-standing progressive tumor through restorative ex vivo activation.
Similar articles
-
Adoptive immunotherapy of advanced tumors with CD62 L-selectin(low) tumor-sensitized T lymphocytes following ex vivo hyperexpansion.J Immunol. 2002 Sep 15;169(6):3314-20. doi: 10.4049/jimmunol.169.6.3314. J Immunol. 2002. PMID: 12218152
-
Treatment of subcutaneous tumor with adoptively transferred T cells.Cell Immunol. 1997 May 25;178(1):24-32. doi: 10.1006/cimm.1997.1124. Cell Immunol. 1997. PMID: 9184695
-
Autolymphocyte therapy. II. Dependence of in vivo anti-tumor specificity and long-term immunity against murine melanoma and carcinoma on ex vivo activated donor memory T-cells.Clin Immunol Immunopathol. 1994 Jun;71(3):325-32. doi: 10.1006/clin.1994.1093. Clin Immunol Immunopathol. 1994. Retraction in: Clin Immunol Immunopathol. 1998 Jun;87(3):314. doi: 10.1006/clin.1997.4497. PMID: 7911078 Retracted.
-
Role of memory T cell subsets for adoptive immunotherapy.Semin Immunol. 2016 Feb;28(1):28-34. doi: 10.1016/j.smim.2016.02.001. Epub 2016 Mar 11. Semin Immunol. 2016. PMID: 26976826 Free PMC article. Review.
-
Immune modulation of inflammatory conditions: regulatory T cells for treatment of GvHD.Immunol Res. 2012 Sep;53(1-3):200-12. doi: 10.1007/s12026-012-8267-9. Immunol Res. 2012. PMID: 22418725 Review.
Cited by
-
Prognostic Impact of Memory CD8(+) T Cells on Immunotherapy in Human Cancers: A Systematic Review and Meta-Analysis.Front Oncol. 2021 Jun 25;11:698076. doi: 10.3389/fonc.2021.698076. eCollection 2021. Front Oncol. 2021. PMID: 34249758 Free PMC article.
-
T cells sensitized with breast tumor progenitor cell vaccine have therapeutic activity against spontaneous HER2/neu tumors.Breast Cancer Res Treat. 2012 Jul;134(1):61-70. doi: 10.1007/s10549-011-1912-5. Epub 2011 Dec 16. Breast Cancer Res Treat. 2012. PMID: 22173696 Free PMC article.
-
Rapid accumulation of adoptively transferred CD8+ T cells at the tumor site is associated with long-term control of SV40 T antigen-induced tumors.Cancer Immunol Immunother. 2008 Jun;57(6):883-95. doi: 10.1007/s00262-007-0424-y. Epub 2007 Nov 15. Cancer Immunol Immunother. 2008. PMID: 18004562 Free PMC article.
-
Cytokine working group study of lymphodepleting chemotherapy, interleukin-2, and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma: clinical outcomes and peripheral-blood cell recovery.J Clin Oncol. 2010 Mar 1;28(7):1196-202. doi: 10.1200/JCO.2009.24.8153. Epub 2010 Feb 1. J Clin Oncol. 2010. PMID: 20124177 Free PMC article. Clinical Trial.
-
Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response.J Immunol Res. 2016;2016:8941260. doi: 10.1155/2016/8941260. Epub 2016 May 22. J Immunol Res. 2016. PMID: 27314056 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous